HIF-1α has generated intense interest as a therapeutic target for inflammatory bowel disease, stemming from the initial observations that HIF-1α knockout animals were protected against chemically-induced colitis, while VHL knockout animals (that exhibit constitutive HIF-1α stabilization) were protected against colitis (81). The gene discussed is VHL; the disease is colitis.